Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07383974
Recruiting Not applicable

The Impact of 12 Week Retention of Nutrients on Skin and the Perception of Physical Health Status

NCT07383974 · tracked via the Priya Life Science China tracker
Sponsor
ChinaNorm
Phase
Not applicable
Started
2025-11-03
Last updated
2026-02-03

Condition(s) studied

Healthy VolunteersDietary SupplementationSkin HealthHealth StatusAntioxidants

Investigational drug(s) / intervention(s)

Vitamin C & Green Tea Capsules + Multivitamin & Mineral Capsules CombinationPlacebo Combination (Matching)

Vitamin C & Green Tea Capsules + Multivitamin & Mineral Capsules Combination: Participants take a combination of active supplements-specifically, Vitamin C \& Green Tea Capsules and Multivitamin \& Mineral Capsules-orally twice daily.

Placebo Combination (Matching): Participants take a matching placebo combination (identical in appearance and taste to the active supplements) orally twice daily

Study summary

This is a randomized, double-blind, placebo-controlled clinical trial exploring the effects of a 12-week dietary supplement regimen on skin condition and perceived overall health status.

The study will involve 120 healthy Chinese adults aged 18 and above with low daily fruit and vegetable intake. Participants will be randomly assigned to one of two groups: one group will take a combination of Nu Skin's Vitamin C \& Green Tea Capsules and Multivitamin \& Mineral Capsules, while the other group will take a matching placebo.

The primary goal is to assess if the supplement combination improves skin health after 12 weeks, measured through specialized facial imaging (assessing spots, redness, evenness) and probe measurements (assessing elasticity, moisture, gloss). Secondary goals include evaluating changes in participants' self-perceived health status (via quality of life, fatigue, and digestive health questionnaires), psychological resilience, memory, and exploring a new method for measuring skin carotenoid levels.

This study is not intended to verify the approved health functions of the products but to explore the potential combined effects of antioxidant and nutritional supplementation on skin and general well-being.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Chinese adults of Asian descent aged 18 and above; 2. Daily fruit and vegetable intake \< 240g (calculated based on the fruit and vegetable section of the food frequency questionnaire); 3. S3 measurement index \< 30000; 4. Participants must possess basic Chinese reading comprehension and expression skills, and be able to independently complete questionnaire surveys; 5. Voluntary participation in the test and signing of the informed consent form; 6. Willingness to comply with all evaluation requirements. Exclusion Criteria: 1. Presence of open facial skin lesions, clearly visible scars, acne marks, etc.; 2. Skin lesions, scars, or significant pigmentation on the hand measurement area; 3. Symptoms of skin disease on the face or hand measurement areas; 4. Having undergone medical aesthetic procedures within the last 6 months; 5. Participation in other clinical trials involving product use within the last 3 months; 6. Use of health supplements or nutritional supplements (e.g., vitamins, minerals) within the last 1 month; 7. Currently planning for pregnancy, pregnant, or lactating; 8. Presence of any disease under current treatment; 9. Any other health issues or chronic diseases that affect behavioral or cognitive abilities; 10. Other iatrogenic reasons identified by experts or professionals that may affect the evaluation results. The S3 instrument refers to a Raman spectroscopy-based biophotonic scanner. The threshold for the S3 screening value is based on previously published literature, which indicated that participants with a daily fruit and vegetable intake of less than 240g had an average Raman spectroscopy biophotonic scanner score below 25,000. However, considering practical recruitment challenges, the inclusion criterion was set at \< 30,000. The S3 device measures the Skin Carotenoid Index, a non-invasive biomarker reflecting skin carotenoid levels.

Primary outcome measure(s)

  • Facial Image Capture VISIA-7 — Imaging sessions are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks)
  • Skin Elasticity Test Probe Cutometer — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks)
  • Skin Gloss Measurement Glossmeter — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks).
  • Skin Moisture Content Corneometer — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks)
  • Skin Hemoglobin Measurement Mexameter MX18 (Courage & Khazaka, Germany) — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks).
  • Skin Moisture Loss Meter Vapometer (Delfin, Finland) — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks).
  • Skin Carotenoid Index — Measurements are conducted at T0 (baseline), T4w (4 weeks), T8w (8 weeks), and T12w (12 weeks).

Trial sites (1)

FacilityCityRegionStatus
Shanghai China-norm Quality Technical Service Co., Ltd. Shanghai Shanghai Municipality Recruiting

More ChinaNorm trials in China

Effects of a 12-Week Solid Beverage Intervention on Suboptimal Health Status Recruiting
Clinical Study of a Facial Cream for Rosacea Recruiting
Pre- and Post-procedure Skin Knowledge Study Recruiting
Clinical Observational Study on Changes in Skin Physiological Parameters Following Ablative and Non-Ablative Fractional Laser Treatment at Different Doses Recruiting
A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis Recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects Starting soon
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers Recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants Recruiting
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07383974 on ClinicalTrials.gov ↗ ← All trials in China